This text is a result of machine translation.
IntoCare Zhang Hui: Ingenuity Forges Quality, Continuous Improvement Safeguards Lives
In 2024, nearly all medical enterprises are exploring overseas markets. This trend is driven by an anti-corruption wave within the medical industry, the demand for financing and initial public offerings, as well as challenges such as excess production capacity. Presently, venturing abroad has become an essential developmental path for medical device enterprises. Successfully entering foreign markets is not only a crucial means for the medical industry to achieve a second grow
May 09, 2024 12:18 PM
Clock in Beijing McDonald's: McDonald's China launched a series of Spring Festival themed activities
Breeding stocks continued to strengthen and aonong biology rose by the limit
Futurtec Adds CE MDR-Certified Knee-Replacement System to Its Orthopedic Robotics Portfolio
Futurtec(鑫君特)has received European Union Medical Device Regulation certification for its ORTHBOT X knee-replacement surgical navigation and positioning system, according to a company announcement reported by MedChina in August.
Aug 27, 2026 03:47 PM
Kanghong’s Conbercept Receives Marketing Authorization in Guyana
Kanghong Pharmaceutical (康弘药业) said its subsidiary Kanghong Bioscience had received a drug registration certificate from Guyana’s Food and Drug Department for conbercept ophthalmic injection, marketed under the brand name Lumitin (朗沐).
Aug 20, 2026 02:48 PM
Tencent launches new brand of games
Beida pharmaceutical: 4510000 shares pledged by Kaiming investment
TECO shares: obtained an invention patent certificate
Wantai BioPharm’s Nine-Valent HPV Vaccine Wins First Overseas Approval in Thailand
Wantai BioPharm (万泰生物) announced on Aug. 11 that the nine-valent HPV vaccine developed by its wholly owned subsidiary, Xiamen Innovax Biotech (万泰沧海), has received marketing authorization from Thailand’s Food and Drug Administration. The approval marks the vaccine’s first clearance outside China and an important step in Wantai BioPharm’s international expansion.
Aug 13, 2026 02:38 PM
Alphamab Licenses Cancer Drug to Pathos AI in Deal Worth More Than US$2.2 Billion
Alphamab Oncology (康宁杰瑞生物制药) has licensed the overseas rights to its experimental cancer drug JSKN016 to US-based Pathos AI in a deal potentially worth more than US$2.2 billion, marking another major overseas licensing agreement for China’s rapidly expanding innovative-drug sector.
Aug 06, 2026 05:41 PM
Bandung special assistant responded: the company can not intervene in the personal debt disputes between dormant shareholders and prominent shareholders, but can only promote them laterally
Guangxi plans to divide real estate enterprises into four credit grades and implement "red blacklist" management
Wan Hongjian: Shuanghui lost more than 800 million yuan due to Bandung's "illegal related party transactions"
Beyond Capital: Why Europe Needs Industrial Partners, Not Just Investors
Aug 04, 2026 11:21 AM
A Small Aircraft, a Bigger Bet: How China's Worthy Aero Plans to Scale Up
Jul 31, 2026 02:44 PM